11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study - Rinne, JO; Brooks, DJ; Rossor, MN (Lancet Neurol, 2010)
et al.